RORC and cancer: Analysis of the overall survival time (OS) revealed that higher RORγ expression in primary cancers was associated with longer overall survival (mean survival of patients without and with cytoplasmic RORγ was 33.4 vs. 43.9 months, respectively, while corresponding values for nuclear RORγ were 30.1 vs. 45.7 months, respectively).